86 related articles for article (PubMed ID: 12664568)
1. Inhibition of 5-LO activating protein (FLAP) activity decreases proteinuria in streptozotocin (STZ)-induced diabetic rats.
Valdivielso JM; Montero A; Munger KA; Badr KF
Adv Exp Med Biol; 2002; 507():79-83. PubMed ID: 12664568
[No Abstract] [Full Text] [Related]
2. Inhibition of 5-lipoxygenase activating protein decreases proteinuria in diabetic rats.
Valdivielso JM; Montero A; Badr KF; Munger KA
J Nephrol; 2003; 16(1):85-94. PubMed ID: 12649539
[TBL] [Abstract][Full Text] [Related]
3. Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.
Frenette R; Hutchinson JH; Léger S; Thérien M; Brideau C; Chan CC; Charleson S; Ethier D; Guay J; Jones TR; McAuliffe M; Piechuta H; Riendeau D; Tagari P; Girard Y
Bioorg Med Chem Lett; 1999 Aug; 9(16):2391-6. PubMed ID: 10476875
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells.
Titos E; Clària J; Planagumà A; López-Parra M; González-Périz A; Gaya J; Miquel R; Arroyo V; Rodés J
J Leukoc Biol; 2005 Oct; 78(4):871-8. PubMed ID: 16033810
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
Wang S; Li Y; Zhao J; Zhang J; Huang Y
Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats.
Voelkel NF; Tuder RM; Wade K; Höper M; Lepley RA; Goulet JL; Koller BH; Fitzpatrick F
J Clin Invest; 1996 Jun; 97(11):2491-8. PubMed ID: 8647941
[TBL] [Abstract][Full Text] [Related]
7. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.
Hakonarson H; Thorvaldsson S; Helgadottir A; Gudbjartsson D; Zink F; Andresdottir M; Manolescu A; Arnar DO; Andersen K; Sigurdsson A; Thorgeirsson G; Jonsson A; Agnarsson U; Bjornsdottir H; Gottskalksson G; Einarsson A; Gudmundsdottir H; Adalsteinsdottir AE; Gudmundsson K; Kristjansson K; Hardarson T; Kristinsson A; Topol EJ; Gulcher J; Kong A; Gurney M; Thorgeirsson G; Stefansson K
JAMA; 2005 May; 293(18):2245-56. PubMed ID: 15886380
[TBL] [Abstract][Full Text] [Related]
8. Discovery of inhibitors of the 5-lipoxygenase activating protein (flap).
Young RN; Gillard JW; Hutchinson JH; Léger S; Prasit P
J Lipid Mediat; 1993; 6(1-3):233-8. PubMed ID: 8357984
[No Abstract] [Full Text] [Related]
9. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
[TBL] [Abstract][Full Text] [Related]
10. Flavonoid rich fraction of Punica granatum improves early diabetic nephropathy by ameliorating proteinuria and disturbed glucose homeostasis in experimental animals.
Ankita P; Deepti B; Nilam M
Pharm Biol; 2015 Jan; 53(1):61-71. PubMed ID: 25289530
[TBL] [Abstract][Full Text] [Related]
11. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
Wang ZS; Xiong F; Xie XH; Chen D; Pan JH; Cheng L
BMC Nephrol; 2015 Mar; 16():44. PubMed ID: 25886386
[TBL] [Abstract][Full Text] [Related]
12. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG
J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
[TBL] [Abstract][Full Text] [Related]
13. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.
Fischer L; Hornig M; Pergola C; Meindl N; Franke L; Tanrikulu Y; Dodt G; Schneider G; Steinhilber D; Werz O
Br J Pharmacol; 2007 Oct; 152(4):471-80. PubMed ID: 17704828
[TBL] [Abstract][Full Text] [Related]
14. The effect of desferrioxamine on the development of renal dysfunction in streptozotocin-induced diabetes.
Whiting PH; Jiffri E; Thomson L; Beaton W; Williamson FW; Long WF
Biochem Soc Trans; 1997 Nov; 25(4):S570. PubMed ID: 9449998
[No Abstract] [Full Text] [Related]
15. [Valibose, an alpha-glucosidase inhibitor, ameliorates the metabolic disorder of glucose and lipids and the nephropathy in streptozotocin-induced diabetic rats].
Liu Q; Liu SN; Sun SJ; Shen ZF
Yao Xue Xue Bao; 2013 Aug; 48(8):1227-32. PubMed ID: 24187828
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of leukotriene biosynthesis improves renal function in experimental glomerulonephritis.
Petric R; Ford-Hutchinson A
J Lipid Mediat Cell Signal; 1995 May; 11(3):231-40. PubMed ID: 7551679
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of Aesculus hippocastanum seeds on diabetic nephropathy in a streptozotocin-induced diabetic rat model.
Elmas O; Erbas O; Yigitturk G
Biomed Pharmacother; 2016 Oct; 83():392-396. PubMed ID: 27424320
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of oxymatrine on experimental diabetic nephropathy.
Guo C; Han F; Zhang C; Xiao W; Yang Z
Planta Med; 2014 Mar; 80(4):269-76. PubMed ID: 24535719
[TBL] [Abstract][Full Text] [Related]
19. The reno-protective effect of aqueous extract of Carum carvi (black zeera) seeds in streptozotocin induced diabetic nephropathy in rodents.
Sadiq S; Nagi AH; Shahzad M; Zia A
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1058-65. PubMed ID: 21060174
[TBL] [Abstract][Full Text] [Related]
20. Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.
Macdonald D; Brideau C; Chan CC; Falgueyret JP; Frenette R; Guay J; Hutchinson JH; Perrier H; Prasit P; Riendeau D; Tagari P; Thérien M; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Mar; 18(6):2023-7. PubMed ID: 18276139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
